 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- U16 / Shanghai Unicar, Rituxan (rituximab) / Roche
Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells) (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3815;
P=N/A
CD20 CAR-T was administered at a target dose of 1.0
- |||| U16 / Shanghai Unicar
New P1/2 trial: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 14, 2023
P1/2, N=100, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- | CD20 specific CAR T / Central South University, Shanghai Unicar
Preclinical, Journal, CAR T-Cell Therapy: Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. (Pubmed Central) - Nov 16, 2022
The effective dose of CAR-T20 in mice starts from 1 × 10 per mouse, equivalent to a clinical dose of 5 × 10/kg. Together, our data support the clinical translation of CAR-T20 for R/R B-cell NHL patients.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4490;
Together, our data support the clinical translation of CAR-T20 for R/R B-cell NHL patients. In conclusion，these findings suggest that the use of CAR T-20 can be served as a salvage therapy in Rituximab-refractory CD20(+) B-cell Non-Hodgkin Lymphoma and raises the possibility of using CAR T-20 in an early disease stage.